Without spending money or knocking it out of the park on sales, IPCI won't be able to hold $1. And the sales aren't up to them, so they are at the mercy of their partners and the market.
I think there is large upside potential from the bottom, but who knows where the bottom is? If they have to raise more money, it could be much lower from the current price.
I think they should make a deal on Glucophage and Keppra at break-even just so they can take advantage of the cashflow. That may be very minimal, I don't know what the market is like for those two.
I don't think it's worth trying to hold $1 just to not get delisted. Odidi would probably be better off finding financing and taking it private or selling the whole thing to IPXL or another generic player (with no or few overlapping products). I don't think it will go for $11/sh, now. Maybe $3.
The FDA really screwed them over, but Odidi has not helped matters.
News 
Market Data 
Discover 
